Aprea Therapeutics, Inc. (APRE)

NASDAQ: APRE · Real-Time Price · USD

0.837

-0.024 (-2.81%)

At close: Apr 28, 2026, 4:00 PM EDT

0.837

0.00 (0.00%)

After-hours: Apr 28, 2026, 4:04 PM EDT

Aprea Therapeutics Employees

Aprea Therapeutics had 8 employees as of December 31, 2025. The number of employees did not change compared to the previous year.

Employees

8

Change (1Y)

n/a

Growth (1Y)

n/a

Revenue / Employee

$35,720

Profits / Employee

-$1,574,946

Market Cap

9.58M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2025	8	0	-
Dec 31, 2024	8	1	14.29%
Dec 31, 2023	7	-2	-22.22%
Dec 31, 2022	9	-	-

Related Stocks

Company Name	Employees
Evogene	52
Imunon	25
BioLineRx	24
Bolt Biotherapeutics	23
CalciMedica	16
Kiora Pharmaceuticals	13
NuCana	12
Enveric Biosciences	6

Employee Rankings

APRE News

7 days ago - Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting - GlobeNewsWire
27 days ago - Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement - GlobeNewsWire
4 weeks ago - Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement - GlobeNewsWire
4 weeks ago - Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial - GlobeNewsWire
6 weeks ago - Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
2 months ago - Aprea Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts
2 months ago - Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars - Benzinga
2 months ago - Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial - GlobeNewsWire